Close

Novavax (NVAX) Says RSV F Vaccine Phase 2 Clinical Trial Data Published in Vaccine

June 7, 2017 8:08 AM EDT Send to a Friend
Novavax, Inc., (Nasdaq: NVAX) today announced that data from the second of two Phase 2 trials of its RSV ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login